Do analysts recommend EXOZ or JMAC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, EXOZ or JMAC?

Maxpro Capital Acquisition has lower revenue, but higher earnings than eXoZymes. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 736.80 -$9.16M -$1.14 N/A Maxpro Capital Acquisition N/A N/A N/A N/A N/A

Is EXOZ or JMAC more profitable?

Maxpro Capital Acquisition's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Maxpro Capital Acquisition N/A N/A N/A

Do analysts rate CHRS or EXOZ?

Coherus Oncology presently has a consensus price target of $8.67, indicating a potential upside of 510.33%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coherus Oncology 0 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.75 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is CHRS or EXOZ more profitable?

Coherus Oncology has a net margin of 397.30% compared to eXoZymes' net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Coherus Oncology 397.30% -198.90% -46.65% eXoZymes N/A -220.63% -141.26%

Do analysts rate EXOZ or SIGA?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Siga Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is EXOZ or SIGA more profitable?

Siga Technologies has a net margin of 21.58% compared to eXoZymes' net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Siga Technologies 21.58% 10.60% 8.94%

Do analysts recommend AVXL or EXOZ?

Anavex Life Sciences currently has a consensus price target of $21.33, indicating a potential upside of 781.54%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Anavex Life Sciences is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anavex Life Sciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is AVXL or EXOZ more profitable?

Anavex Life Sciences' return on equity of -38.76% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets Anavex Life Sciences N/A -38.76% -35.01% eXoZymes N/A -220.63% -141.26%

Does the media favor AVXL or EXOZ?

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 1 articles in the media. Anavex Life Sciences' average media sentiment score of 1.34 beat eXoZymes' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anavex Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate EXOZ or OTLK?

Oncobiologics has a consensus price target of $6.50, suggesting a potential upside of 371.01%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Oncobiologics 1 Sell rating(s) 5 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is EXOZ or OTLK more profitable?

Oncobiologics' return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Oncobiologics N/A N/A -291.28%

Does the media favor EXOZ or OTLK?

In the previous week, Oncobiologics had 3 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Oncobiologics and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.00 beat Oncobiologics' score of -0.55 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Oncobiologics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Negative

eXoZymes (EXOZ) Competitors

$5.60 -0.42 (-6.98%)

Closing price 07/20/2026 03:47 PM Eastern

Extended Trading

$5.45 -0.15 (-2.68%)

As of 07/20/2026 07:34 PM Eastern

Compare

EXOZ vs. JMAC, CHRS, SIGA, AVXL, and OTLK

Should you buy eXoZymes stock or one of its competitors? MarketBeat compares eXoZymes with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with eXoZymes include Maxpro Capital Acquisition (JMAC), Coherus Oncology (CHRS), Siga Technologies (SIGA), Anavex Life Sciences (AVXL), and Oncobiologics (OTLK). These companies are all part of the "pharmaceutical products" industry.

How does eXoZymes compare to Maxpro Capital Acquisition?

eXoZymes (NASDAQ:EXOZ) and Maxpro Capital Acquisition (NASDAQ:JMAC) are both small-cap pharmaceutical products companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Maxpro Capital Acquisition has lower revenue, but higher earnings than eXoZymes.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	736.80	-$9.16M	-$1.14	N/A
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A

eXoZymes has a beta of 2.73, meaning that its stock price is 173% more volatile than the broader market. Comparatively, Maxpro Capital Acquisition has a beta of 0.01, meaning that its stock price is 99% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Maxpro Capital Acquisition's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Maxpro Capital Acquisition	N/A	N/A	N/A

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. 72.4% of eXoZymes shares are held by insiders. Comparatively, 19.3% of Maxpro Capital Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, eXoZymes had 1 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for Maxpro Capital Acquisition. eXoZymes' average media sentiment score of 0.00 equaled Maxpro Capital Acquisition'saverage media sentiment score.

Company	Overall Sentiment
eXoZymes	Neutral
Maxpro Capital Acquisition	Neutral

Summary

eXoZymes beats Maxpro Capital Acquisition on 5 of the 8 factors compared between the two stocks.

How does eXoZymes compare to Coherus Oncology?

Coherus Oncology (NASDAQ:CHRS) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk, profitability and valuation.

Coherus Oncology has a beta of 0.97, indicating that its share price is 3% less volatile than the broader market. Comparatively, eXoZymes has a beta of 2.73, indicating that its share price is 173% more volatile than the broader market.

Coherus Oncology has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Coherus Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coherus Oncology	$42.17M	5.19	$168.02M	$1.67	0.85
eXoZymes	$70K	736.80	-$9.16M	-$1.14	N/A

In the previous week, eXoZymes had 1 more articles in the media than Coherus Oncology. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for Coherus Oncology. Coherus Oncology's average media sentiment score of 0.00 equaled eXoZymes'average media sentiment score.

Company	Overall Sentiment
Coherus Oncology	Neutral
eXoZymes	Neutral

Coherus Oncology presently has a consensus price target of $8.67, indicating a potential upside of 510.33%. Given Coherus Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Coherus Oncology is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coherus Oncology	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

72.8% of Coherus Oncology shares are owned by institutional investors. 8.1% of Coherus Oncology shares are owned by company insiders. Comparatively, 72.4% of eXoZymes shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Coherus Oncology has a net margin of 397.30% compared to eXoZymes' net margin of 0.00%. Coherus Oncology's return on equity of -198.90% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coherus Oncology	397.30%	-198.90%	-46.65%
eXoZymes	N/A	-220.63%	-141.26%

Summary

Coherus Oncology beats eXoZymes on 11 of the 15 factors compared between the two stocks.

How does eXoZymes compare to Siga Technologies?

eXoZymes (NASDAQ:EXOZ) and Siga Technologies (NASDAQ:SIGA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, media sentiment, dividends, analyst recommendations and risk.

Siga Technologies has higher revenue and earnings than eXoZymes. eXoZymes is trading at a lower price-to-earnings ratio than Siga Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	736.80	-$9.16M	-$1.14	N/A
Siga Technologies	$94.57M	2.64	$23.28M	$0.27	12.89

Siga Technologies has a net margin of 21.58% compared to eXoZymes' net margin of 0.00%. Siga Technologies' return on equity of 10.60% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Siga Technologies	21.58%	10.60%	8.94%

In the previous week, eXoZymes had 1 more articles in the media than Siga Technologies. MarketBeat recorded 1 mentions for eXoZymes and 0 mentions for Siga Technologies. eXoZymes' average media sentiment score of 0.00 equaled Siga Technologies'average media sentiment score.

Company	Overall Sentiment
eXoZymes	Neutral
Siga Technologies	Neutral

55.4% of Siga Technologies shares are held by institutional investors. 72.4% of eXoZymes shares are held by company insiders. Comparatively, 2.7% of Siga Technologies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

eXoZymes has a beta of 2.73, suggesting that its share price is 173% more volatile than the broader market. Comparatively, Siga Technologies has a beta of 0.96, suggesting that its share price is 4% less volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Siga Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Siga Technologies beats eXoZymes on 8 of the 12 factors compared between the two stocks.

How does eXoZymes compare to Anavex Life Sciences?

Anavex Life Sciences (NASDAQ:AVXL) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

eXoZymes has higher revenue and earnings than Anavex Life Sciences. Anavex Life Sciences is trading at a lower price-to-earnings ratio than eXoZymes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anavex Life Sciences	N/A	N/A	-$46.38M	-$0.46	N/A
eXoZymes	$70K	736.80	-$9.16M	-$1.14	N/A

31.6% of Anavex Life Sciences shares are held by institutional investors. 11.0% of Anavex Life Sciences shares are held by company insiders. Comparatively, 72.4% of eXoZymes shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Anavex Life Sciences' return on equity of -38.76% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anavex Life Sciences	N/A	-38.76%	-35.01%
eXoZymes	N/A	-220.63%	-141.26%

Anavex Life Sciences currently has a consensus price target of $21.33, indicating a potential upside of 781.54%. Given Anavex Life Sciences' stronger consensus rating and higher possible upside, research analysts plainly believe Anavex Life Sciences is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anavex Life Sciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Anavex Life Sciences has a beta of 1.14, suggesting that its stock price is 14% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.73, suggesting that its stock price is 173% more volatile than the broader market.

In the previous week, Anavex Life Sciences and Anavex Life Sciences both had 1 articles in the media. Anavex Life Sciences' average media sentiment score of 1.34 beat eXoZymes' score of 0.00 indicating that Anavex Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anavex Life Sciences	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Anavex Life Sciences beats eXoZymes on 8 of the 13 factors compared between the two stocks.

How does eXoZymes compare to Oncobiologics?

eXoZymes (NASDAQ:EXOZ) and Oncobiologics (NASDAQ:OTLK) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, risk, earnings, profitability, analyst recommendations and valuation.

In the previous week, Oncobiologics had 3 more articles in the media than eXoZymes. MarketBeat recorded 4 mentions for Oncobiologics and 1 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.00 beat Oncobiologics' score of -0.55 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Oncobiologics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Negative

11.2% of Oncobiologics shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by company insiders. Comparatively, 1.8% of Oncobiologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

eXoZymes has higher earnings, but lower revenue than Oncobiologics. eXoZymes is trading at a lower price-to-earnings ratio than Oncobiologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	736.80	-$9.16M	-$1.14	N/A
Oncobiologics	$1.35M	151.89	-$62.42M	-$1.17	N/A

eXoZymes has a beta of 2.73, meaning that its share price is 173% more volatile than the broader market. Comparatively, Oncobiologics has a beta of 0.77, meaning that its share price is 23% less volatile than the broader market.

Oncobiologics has a consensus price target of $6.50, suggesting a potential upside of 371.01%. Given Oncobiologics' stronger consensus rating and higher probable upside, analysts clearly believe Oncobiologics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Oncobiologics	1 Sell rating(s)	5 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Oncobiologics' return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Oncobiologics	N/A	N/A	-291.28%

Summary

Oncobiologics beats eXoZymes on 8 of the 15 factors compared between the two stocks.

Get eXoZymes News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXOZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EXOZ vs. The Competition

Export

Metric	eXoZymes	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$55.45M	$3.69B	$6.89B	$12.28B
Dividend Yield	N/A	2.16%	2.67%	9.39%
P/E Ratio	-4.91	20.49	27.07	23.94
Price / Sales	736.80	300.32	515.45	90.30
Price / Cash	N/A	60.31	26.68	47.25
Price / Book	14.00	7.92	10.42	6.14
Net Income	-$9.16M	$23.81M	$3.60B	$331.74M
7 Day Performance	-20.00%	-1.09%	-1.26%	-1.81%
1 Month Performance	-28.48%	2.56%	1.07%	-1.44%
1 Year Performance	-40.80%	42.16%	23.61%	16.33%

eXoZymes Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EXOZ eXoZymes	0.1218 of 5 stars	$5.60 -7.0%	N/A	-39.5%	$55.45M	$70K	N/A	29	Gap Down
JMAC Maxpro Capital Acquisition	N/A	$18.95 +0.8%	N/A	+198.2%	$254.46M	N/A	N/A	2,021
CHRS Coherus Oncology	2.1929 of 5 stars	$1.54 -5.5%	$8.67 +462.8%	+61.2%	$251.43M	$42.17M	0.92	330
SIGA Siga Technologies	0.4034 of 5 stars	$3.59 +2.6%	N/A	-47.4%	$251.03M	$94.57M	13.30	40
AVXL Anavex Life Sciences	2.7668 of 5 stars	$2.50 -7.4%	$21.33 +753.3%	-78.0%	$250.21M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EXOZ) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

eXoZymes (EXOZ) Competitors

EXOZ vs. JMAC, CHRS, SIGA, AVXL, and OTLK

How does eXoZymes compare to Maxpro Capital Acquisition?

Summary

How does eXoZymes compare to Coherus Oncology?

Summary

How does eXoZymes compare to Siga Technologies?

Summary

How does eXoZymes compare to Anavex Life Sciences?

Summary

How does eXoZymes compare to Oncobiologics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

eXoZymes (EXOZ) Competitors

EXOZ vs. JMAC, CHRS, SIGA, AVXL, and OTLK

How does eXoZymes compare to Maxpro Capital Acquisition?

Which has higher valuation & earnings, EXOZ or JMAC?

Which has more risk & volatility, EXOZ or JMAC?

Do analysts recommend EXOZ or JMAC?

Is EXOZ or JMAC more profitable?

Do institutionals & insiders have more ownership in EXOZ or JMAC?

Does the media refer more to EXOZ or JMAC?

Summary

How does eXoZymes compare to Coherus Oncology?

Which has more volatility & risk, CHRS or EXOZ?

Which has preferable valuation and earnings, CHRS or EXOZ?

Does the media refer more to CHRS or EXOZ?

Do analysts rate CHRS or EXOZ?

Do institutionals and insiders believe in CHRS or EXOZ?

Is CHRS or EXOZ more profitable?

Summary

How does eXoZymes compare to Siga Technologies?

Which has stronger valuation & earnings, EXOZ or SIGA?

Is EXOZ or SIGA more profitable?

Does the media refer more to EXOZ or SIGA?

Do institutionals and insiders believe in EXOZ or SIGA?

Which has more volatility & risk, EXOZ or SIGA?

Do analysts rate EXOZ or SIGA?

Summary

How does eXoZymes compare to Anavex Life Sciences?

Which has better valuation & earnings, AVXL or EXOZ?

Do institutionals & insiders believe in AVXL or EXOZ?

Is AVXL or EXOZ more profitable?

Do analysts recommend AVXL or EXOZ?

Which has more risk & volatility, AVXL or EXOZ?

Does the media favor AVXL or EXOZ?

Summary

How does eXoZymes compare to Oncobiologics?

Does the media favor EXOZ or OTLK?

Do institutionals and insiders hold more shares of EXOZ or OTLK?

Which has stronger earnings & valuation, EXOZ or OTLK?

Which has more volatility and risk, EXOZ or OTLK?

Do analysts rate EXOZ or OTLK?

Is EXOZ or OTLK more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EXOZ vs. The Competition

eXoZymes Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools